Last reviewed · How we verify

Aspirin and Clopidogrel

Assistance Publique - Hôpitaux de Paris · FDA-approved active Small molecule

Aspirin and Clopidogrel is a Antiplatelet agent (dual therapy) Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently FDA-approved for Acute coronary syndrome, Secondary prevention after myocardial infarction, Prevention of stent thrombosis after percutaneous coronary intervention. Also known as: Aspirin: acid acetylsalycilic, Clopidogrel: plavix, Aspirin Enteric Coated Tablets ,Bayer HealthCare AG ;, Plavix.

Aspirin and clopidogrel together inhibit platelet aggregation through different pathways to prevent blood clots.

Aspirin and clopidogrel together inhibit platelet aggregation through different pathways to prevent blood clots. Used for Acute coronary syndrome, Secondary prevention after myocardial infarction, Prevention of stent thrombosis after percutaneous coronary intervention.

At a glance

Generic nameAspirin and Clopidogrel
Also known asAspirin: acid acetylsalycilic, Clopidogrel: plavix, Aspirin Enteric Coated Tablets ,Bayer HealthCare AG ;, Plavix, Aspirin Enteric Coated Tablets
SponsorAssistance Publique - Hôpitaux de Paris
Drug classAntiplatelet agent (dual therapy)
TargetCyclooxygenase (COX) and P2Y12 receptor
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Aspirin irreversibly inhibits cyclooxygenase (COX), reducing thromboxane A2 production and platelet activation. Clopidogrel is a P2Y12 receptor antagonist that blocks ADP-mediated platelet aggregation. Combined, they provide dual antiplatelet therapy with complementary mechanisms to reduce thrombotic events.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Aspirin and Clopidogrel

What is Aspirin and Clopidogrel?

Aspirin and Clopidogrel is a Antiplatelet agent (dual therapy) drug developed by Assistance Publique - Hôpitaux de Paris, indicated for Acute coronary syndrome, Secondary prevention after myocardial infarction, Prevention of stent thrombosis after percutaneous coronary intervention.

How does Aspirin and Clopidogrel work?

Aspirin and clopidogrel together inhibit platelet aggregation through different pathways to prevent blood clots.

What is Aspirin and Clopidogrel used for?

Aspirin and Clopidogrel is indicated for Acute coronary syndrome, Secondary prevention after myocardial infarction, Prevention of stent thrombosis after percutaneous coronary intervention.

Who makes Aspirin and Clopidogrel?

Aspirin and Clopidogrel is developed and marketed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

Is Aspirin and Clopidogrel also known as anything else?

Aspirin and Clopidogrel is also known as Aspirin: acid acetylsalycilic, Clopidogrel: plavix, Aspirin Enteric Coated Tablets ,Bayer HealthCare AG ;, Plavix, Aspirin Enteric Coated Tablets.

What drug class is Aspirin and Clopidogrel in?

Aspirin and Clopidogrel belongs to the Antiplatelet agent (dual therapy) class. See all Antiplatelet agent (dual therapy) drugs at /class/antiplatelet-agent-dual-therapy.

What development phase is Aspirin and Clopidogrel in?

Aspirin and Clopidogrel is FDA-approved (marketed).

What are the side effects of Aspirin and Clopidogrel?

Common side effects of Aspirin and Clopidogrel include Bleeding, Gastrointestinal bleeding, Dyspepsia, Bruising, Thrombotic thrombocytopenic purpura (TTP).

What does Aspirin and Clopidogrel target?

Aspirin and Clopidogrel targets Cyclooxygenase (COX) and P2Y12 receptor and is a Antiplatelet agent (dual therapy).

Related